DS-3939 is under clinical development by Glycotope and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DS-3939’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DS-3939 overview
DS-3939 is under development for the treatment of locally advanced, metastatic, or unresectable solid tumors like urothelial, non-small cell lung, breast, ovarian, or biliary tract cancers, or pancreatic ductal adenocarcinoma. It is administered through intravenous route. The drug candidate comprises of humanized anti-TA-MUC1 antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) through tetrapeptide-based cleavable linkers. It is being developed based on DXd ADC platform which produce glyco-optimized antibodies.
Glycotope overview
Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. The company pipeline products include GT-002 (LYPD3), GT-001, GT-00A and GT-00A based IL-15 immuno-cytokine. Glycotope product indications include breast cancers non-small cell lung cancer, colorectal cancer, head and neck cancer, small cell lung cancer and ovarian cancer, squamous cell carcinoma of the head and neck, primary tumor, metastases and cancer stem cells. The company also developed a target-discovery approach that enables us to identify proteins that carry aberrant glycosylation if expressed in cancerous tissues of several indications. Glycotope is headquartered in Berlin, Germany.
For a complete picture of DS-3939’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
